News - Neurological, Eli Lilly

Filter

Current filters:

NeurologicalEli Lilly

Popular Filters

1 to 25 of 32 results

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

14-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to fund paliperidone…

Eli LillyHealthcareInvega SustennaJohnson & JohnsonNeurologicalNew ZealandPharmaceuticalPricingRisperdal ConstaZyprexa Relprevv

Lilly buys back CGRP antibody for migraine prevention from Arteaus Therapeutics

Lilly buys back CGRP antibody for migraine prevention from Arteaus Therapeutics

13-01-2014

Based on positive Phase II data, US drug major Eli Lilly has acquired all development rights for a calcitonin…

Arteaus TherapeuticsEli LillyLicensingLY2951742NeurologicalPharmaceutical

UK Dementia Consortium to bridge the gap between academia and pharma

UK Dementia Consortium to bridge the gap between academia and pharma

11-12-2013

The UK has today announced a new £3 million ($4.9 million) Dementia Consortium bringing together research…

EisaiEli LillyNeurologicalPharmaceuticalPoliticsResearchUK

Eli Lilly drops edivoxetine as adjunctive therapy for MDD

Eli Lilly drops edivoxetine as adjunctive therapy for MDD

06-12-2013

Given that results from three late-stage studies of edivoxetine did not meet the primary study objective…

edivoxetineEli LillyNeurologicalPharmaceutical

New Zealand views access to sugammadex and atomoxetine and baclofen injection funding

02-12-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on the following proposals…

Asia-PacificBridionEli LillyLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalRegulationStrattera

Through 2022, growth in the neuropathic pain drug market will be constrained by generics

05-11-2013

The loss of US and European market exclusivity of three sales-leading neuropathic pain (NP) agents -…

Asia-PacificCymbaltaEli LillyEndo PharmaceuticalsEuropeLidodermLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Lundbeck/Takeda's Brintellix has blockbuster potential

02-08-2013

Denmark CNS drug specialist Lundbeck (LUND: CO) and partner Japanese drug major Takeda Pharmaceutical's…

BrintellixedivoxetineEli LillyFetzimaForest LaboratoriesGenericsGlobalLundbeckMarkets & MarketingNeurologicalPharmaceuticalPierre FabreTakeda Pharmaceuticals

FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv

19-06-2013

The US Food and Drug Administration yesterday (June 18) revealed it is investigating two unexplained…

Eli LillyNeurologicalNorth AmericaPharmaceuticalRegulationZyprexa

Lilly stops Ph II study of Alzheimer's candidate LY2886721 due to abnormal liver tests

14-06-2013

US drug major Eli Lilly (NYSE: LLY) says it has stopped its Phase II study (BACC) for LY2886721, a beta…

Eli LillyLY2886721NeurologicalPharmaceuticalResearch

Shire's Elvanse shows significantly faster response in ADHD symptoms than Strattera

07-06-2013

Ireland-headquartered Shire (LSE: SHP, NASDAQ: SHPG) presented positive scientific data comparing the…

Eli LillyElvanseNeurologicalPharmaceuticalResearchShireStrattera

AAA enters supply deal with Eli Lilly for Amyvid in France, Italy and Spain

24-05-2013

France-based molecular nuclear medicine firm Advanced Accelerator Applications (AAA) says it has signed…

Advanced Accelerator ApplicationsAmyvidEli LillyNeurologicalPharmaceuticalProduction

Lilly drops enzastaurin development; Remoxy future viewed by Pfizer and partners

10-05-2013

US drug major Eli Lilly (NYSE: LLY) revealed that Phase III clinical trial results from enzastaurin's…

DurectEli LillyenzastaurinNeurologicalOncologyPain TherapeuticsPfizerPharmaceuticalRegulationRemoxyResearch

Shire settles with Actavis/Watson over Intuniv; Lilly sues J&J

26-04-2013

Ireland-headquartered Shire (LSE: SHP) says it has settled all pending litigation with Actavis (NYSE:…

ActavisEli LillyGenericsIntunivJohnson & JohnsonNeurologicalNorth AmericaPatentsPharmaceuticalShiresolanezumabWatson Pharmaceuticals

Lilly plans new trial of Alzheimer's hope solanezumab

13-12-2012

US drug major Eli Lilly (NYSE: LLY) is planning to carry out an additional Phase III trial of its Alzheimer's…

Eli LillyNeurologicalPharmaceuticalResearchsolanezumab

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada

02-11-2012

US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial

11-10-2012

Leading scientists at the USA's Washington University at St Louis have selected the first drugs to be…

BiotechnologyEli LillygantenerumabNeurologicalPharmaceuticalResearchRochesolanezumab

Mixed results with Eli Lilly Alzheimer's drug solanezumab, but investors pleased

09-10-2012

US pharma major Eli Lilly (NYSE: LLY) yesterday reported detailed results from two Phase III studies…

BiotechnologyEli LillyNeurologicalPharmaceuticalResearchsolanezumab

Lilly halts development of schizophrenia candidate pomaglumetad methionil

30-08-2012

US drug major Eli Lilly (NYSE: LLY) saw its shares dip less than 1% to $44.51 in morning trading yesterday,…

Eli LillyFinancialNeurologicalPharmaceuticalpomaglumetad methionilResearch

Mixed news on Lilly's Alzheimer's drug solanezumab; Alimta patent upheld

28-08-2012

US drug major Eli Lilly (NYSE: LLY) revealed last Friday that the primary endpoints, both cognitive and…

AlimtaEli LillyLegalNeurologicalNorth AmericaOncologyPatentsPharmaceuticalResearchsolanezumabTeva Pharmaceutical Industries

Lilly/Boehringer Ingelheim's Cymbalta now fibromyalgia market leader in USA

22-07-2012

US drug major Eli Lilly (NYSE: LLY) and German independent Boehringer Ingelheim's Cymbalta (duloxetine)…

Boehringer IngelheimCymbaltaEli LillyGlobalLyricaMarkets & MarketingNeurologicalNorth AmericaPfizerPharmaceutical

Lilly's pomaglumetad methionil fails to meet clinical endpoint

12-07-2012

US drug major Eli Lilly (NYSE: LLY) announced today negative clinical trial results from study H8Y-MC-HBBM…

Eli LillyNeurologicalPharmaceuticalpomaglumetad methionilResearch

1 to 25 of 32 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top